We are thrilled to announce the publication of the first-in-human study on Neurocritical Care.
Our group has developed a technology – CB240_Aurora – that allows selective brain temperature management with a highly portable device, thus maximizing neuroprotection while minimizing systemic side effects. Thanks to its portability, the technology may also allow the early application of TTM in out-of-hospital settings (i.e., ambulances) and continuity of care when patients are transferred out of the ICU for imaging or emergency surgery.
Here, we report the first-in-human study of the technology, sponsored by a grant from the National Institute for Health and Care Research Brain Injury MedTech Co-operative.
⬇ Full article ⬇
https://link.springer.com/article/10.1007/s12028-023-01800-7
Comments are closed.